Literature DB >> 6230467

Nontransmission of T-cell subset abnormalities from hemophiliacs to their spouses.

J K Kreiss, C K Kasper, J L Fahey, M Weaver, B R Visscher, J A Stewart, D N Lawrence.   

Abstract

Hemophiliacs who are exposed to pooled clotting factor concentrate constitute one group at increased risk for development of acquired immune deficiency syndrome. To determine the prevalence of cellular immune aberrations in asymptomatic hemophiliacs, we studied a group of 65 adult hemophiliacs for T-cell subset abnormalities. Sixty-five percent of concentrate recipients had an abnormal T-helper to T-suppressor cell ratio, 40% had a depressed absolute T-helper cell level, and 29% had an elevated absolute T-suppressor cell count. To determine whether horizontal transmission of T-cell subset abnormalities from hemophiliacs to their female sexual partners occurred, we studied 41 spouses. We found no correlation between paired husband and wife values for T-cell ratio or any other immune parameter studied. There were no significant differences found between wives of hemophiliacs with reversed T-cell ratios and wives of hemophiliacs with T-cell ratios of 1.0 or greater, with respect to immunologic tests. We conclude that there is no evidence to date for heterosexual or household-contact transmission of T-cell subset abnormalities from hemophiliacs to their spouses in our study population.

Entities:  

Mesh:

Year:  1984        PMID: 6230467

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Commentary: non-HIV hypotheses must be studied more carefully.

Authors:  P Duesberg
Journal:  BMJ       Date:  1996-01-27

2.  Heterosexual transmission of HIV in hemophiliacs.

Authors:  T Kamradt; D Niese; H H Brackmann; K E Schneweis; B Kamps; B van Loo; P Euler
Journal:  Klin Wochenschr       Date:  1990-12-17

Review 3.  Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV.

Authors:  P H Duesberg
Journal:  Genetica       Date:  1995       Impact factor: 1.082

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.